FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200047841> ?p ?o ?g. }

• W4200047841 endingPage "236" @default.
• W4200047841 startingPage "234" @default.
• W4200047841 abstract "According to WHO, SARS-CoV-2 is estimated to have caused 265 million infections and more than 5 million deaths over the past 2 years. Current vaccines are based on the original SARS-CoV-2 strain and are designed primarily to raise an antibody response against the spike protein (S), although elicited T-cell responses can also contribute to protection from severe disease. The SARS-CoV-2 RNA polymerase is intrinsically error prone, which results in mutation to the viral genome. In the past year, several variants containing multiple mutations in S have been reported: alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2). These variants contain mutations in the receptor binding motif, a small 25 amino acid patch at the tip of S that mediates interaction with the ACE2 receptor (one mutation in alpha, three in beta and gamma, and two in delta). These changes can lead to increased transmissibility by increasing affinity to ACE2 (by seven times for alpha, 19 times for both beta and gamma, and double for delta)1Zahradník J Tuekprakhon A Ginn HM et al.Receptor binding and escape from beta antibody responses drive omicron-B.1.1.529 evolution.bioRxiv. 2021; (published online Dec 7.) (preprint).https://doi.org/10.1101/2021.12.03.471045Google Scholar or lead to immune escape. First alpha and then delta variants spread globally causing successive waves of infection, while large localised outbreaks were caused in southern Africa by the beta variant and in South America by the gamma variant. At present, delta is estimated to have caused more than 99% of infections worldwide; however, a new variant of concern, omicron (B.1.1.529), was reported first in South Africa on Nov 24, 2021,2WHOClassification of omicron (B.1.1.529): SARS-CoV-2 variant of concern.https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concernDate accessed: December 13, 2021Google Scholar but has since been reported in multiple countries. Early reports from South Africa suggest that omicron is highly transmissible, in a population where 60–80% already show serological evidence of previous infection or vaccination, suggesting that omicron is able to break through natural and vaccine-induced immunity; although early reports do not indicate more severe disease. Omicron contains a large number of mutations in S compared with previous variants of concern, mostly concentrated around the receptor binding motif: 30 amino acid substitutions, deletion of six residues, and insertion of three residues.1Zahradník J Tuekprakhon A Ginn HM et al.Receptor binding and escape from beta antibody responses drive omicron-B.1.1.529 evolution.bioRxiv. 2021; (published online Dec 7.) (preprint).https://doi.org/10.1101/2021.12.03.471045Google Scholar Mutations are also present at other sites (receptor binding domain and N-terminal domain) which might affect neutralising antibodies. There is concern that omicron will lead to increased propensity to infect individuals who have received vaccines, whose antigens are based on the original S sequence. Here, we report the results of neutralisation assays using an isolate of omicron obtained from an infected case in the UK. Neutralisation assays were done on sera from individuals from the immunology cohort of the Com-COV2 study,3Stuart ASVS Shaw RH Liu X et al.Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.Lancet. 2021; (published online Dec 6.)https://doi.org/10.1016/S0140-6736(21)02718-5Summary Full Text Full Text PDF Scopus (38) Google Scholar who were seronegative at enrolment (defined by anti-nucleocapsid IgG). Participants were vaccinated with two doses of Oxford–AstraZeneca's ChAdOx1 nCoV-19 (ChAd; n=22), or two doses of Pfizer–BioNTech's BNT162b2 (BNT; n=21) with a priming interval of 8–11 (median 9) weeks. Samples were obtained 28 days (range 25–32) following the second immunisation (appendix p 1).3Stuart ASVS Shaw RH Liu X et al.Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.Lancet. 2021; (published online Dec 6.)https://doi.org/10.1016/S0140-6736(21)02718-5Summary Full Text Full Text PDF Scopus (38) Google Scholar Live virus neutralisation titres against omicron are compared with titres against Victoria, an early pandemic SARS-CoV-2 strain, together with titres against beta and delta variants. Neutralising titres on sera from participants who had received homologous ChAd dropped to below the detectable threshold in all but one participant (figure A, B). Median neutralising titres on sera from participants who had received homologous BNT reduced by 29·8 fold from 1609 (Victoria strain) to 54 (omicron variant), with one participant dropping below the detection threshold. In most cases, samples that did not neutralise with 50% focus reduction neutralisation titres at a dilution of less than 1/20 showed some residual neutralising activity (figure 1C). In summary, there was a substantial decrease in neutralisation titre in recipients of both homologous ChAd and BNT primary courses, with evidence of some recipients not neutralising at all. This reduction in neutralisation titre will probably be more pronounced at later timepoints. These data, although derived from a relatively small sample size, are consistent with published data from datasets of similar size.4Cele S Jackson L Khan K et al.SARS-CoV-2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection.medRxiv. 2021; (published online Dec 9.) (preprint).https://doi.org/10.1101/2021.12.08.21267417Google Scholar, 5Roessler A Riepler L Bante D von Laer D Kimpel J SARS-CoV-2 B.1.1.529 variant (omicron) evades neutralization by sera from vaccinated and convalescent individuals.medRxiv. 2021; (published online Dec 11.) (preprint).https://doi.org/10.1101/2021.12.08.21267491Google Scholar, 6Wilhelm A Widera M Grikscheit K et al.Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies.medRxiv. 2021; (published online Dec 8.) (preprint).https://doi.org/10.1101/2021.12.07.21267432Google Scholar Together, the findings suggest that omicron is more antigenically distant from the original SARS-CoV-2 vaccine strain than the previously most distant strains, beta and delta. Preliminary data from the UK Health Security Agency7UK Health Security AgencySARS-CoV-2 variants of concern and variants under investigation in England. 2021. Technical briefing 31.https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdfDate: Dec 10, 2021Date accessed: December 13, 2021Google Scholar have shown reduced effectiveness against symptomatic infection after two doses of ChAd or BNT, suggesting a result of increased breakthrough infections in previously infected or double vaccinated individuals, which could drive a further wave of infection. The effect on disease severity is unknown, although there is currently no evidence of increased potential to cause severe disease, hospitalisation, or death. It could be that other aspects of the immune response such as non-neutralising antibodies and cellular immunity, which are not expected to be as severely affected by this variant, could confer a degree of protection against severe disease. However, it should be noted that higher transmission will inevitably lead to increased numbers of cases and a greater burden on health systems, even without proportional changes in severity. Possessing a high starting neutralisation titre against early pandemic strains gives a higher level of neutralisation of omicron, which could be obtained by deploying third booster doses of vaccine. There is some reassurance that a third dose of a COVID-19 vaccine does indeed increase vaccine effectiveness against the omicron variant,7UK Health Security AgencySARS-CoV-2 variants of concern and variants under investigation in England. 2021. Technical briefing 31.https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdfDate: Dec 10, 2021Date accessed: December 13, 2021Google Scholar and testing of samples from Cov-BOOST8Munro APS Janani L Cornelius V et al.Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.Lancet. 2021; (published online Dec 2.)https://doi.org/10.1016/S0140-6736(21)02717-3Summary Full Text Full Text PDF Scopus (133) Google Scholar will provide further information on the immunology underlying this. Together, these findings will provide further understanding of the potential for a boosting strategy as a control measure for omicron infection and transmission. Should omicron, as expected, become the dominant strain worldwide, given its antigenic distance from ancestral strains, it could be necessary to produce vaccines tailored to omicron; however, these might be unlikely to give protection against previous strains. This development might stimulate consideration of a switch from the current monovalent vaccine strategy towards multivalent formulations currently used in seasonal influenza vaccines. In the meantime, reaching people who are unvaccinated with current vaccines is a priority, in order to reduce transmission levels and the potential for severe disease in people who are immunologically naive. GRS sits on the GSK Vaccines Scientific Advisory Board and is a founder member of RQ Biotechnology. MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM Vaccines. He receives no personal financial payment for this work. AJP reports grants from UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, and National Institute for Health Research. AJP is chair of Department of Health and Social Care (DHSC)'s England Joint Committee on Vaccination and Immunisation (JCVI), but does not participate in discussions on COVID-19 vaccines, and is a member of the WHO's Scientific Advisory Group for Emergencies. The views expressed in this Correspondence are those of the authors and do not necessarily represent the views of the DHSC, JCVI, NIHR, or WHO. The University of Oxford has entered into a partnership with AstraZeneca for the development of a coronavirus vaccine. JSN-V-T is seconded to the DHSC. WD, RHS, and PS contributed equally and are joint first authors. All other authors declare no competing interests. MDS and GRS are joint senior authors. Download .pdf (.2 MB) Help with pdf files Supplementary appendix" @default.
• W4200047841 created "2021-12-31" @default.
• W4200047841 creator A5000793343 @default.
• W4200047841 creator A5008207321 @default.
• W4200047841 creator A5022256556 @default.
• W4200047841 creator A5024393155 @default.
• W4200047841 creator A5034961076 @default.
• W4200047841 creator A5047931301 @default.
• W4200047841 creator A5059959150 @default.
• W4200047841 creator A5065914659 @default.
• W4200047841 creator A5067708123 @default.
• W4200047841 creator A5067773219 @default.
• W4200047841 creator A5069883240 @default.
• W4200047841 creator A5072476030 @default.
• W4200047841 creator A5088147193 @default.
• W4200047841 creator A5089282433 @default.
• W4200047841 date "2022-01-01" @default.
• W4200047841 modified "2023-10-14" @default.
• W4200047841 title "Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum" @default.
• W4200047841 cites W4200133104 @default.
• W4200047841 cites W4226343533 @default.
• W4200047841 doi "https://doi.org/10.1016/s0140-6736(21)02844-0" @default.
• W4200047841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34942101" @default.
• W4200047841 hasPublicationYear "2022" @default.
• W4200047841 type Work @default.
• W4200047841 citedByCount "278" @default.
• W4200047841 countsByYear W42000478412021 @default.
• W4200047841 countsByYear W42000478412022 @default.
• W4200047841 countsByYear W42000478412023 @default.
• W4200047841 crossrefType "journal-article" @default.
• W4200047841 hasAuthorship W4200047841A5000793343 @default.
• W4200047841 hasAuthorship W4200047841A5008207321 @default.
• W4200047841 hasAuthorship W4200047841A5022256556 @default.
• W4200047841 hasAuthorship W4200047841A5024393155 @default.
• W4200047841 hasAuthorship W4200047841A5034961076 @default.
• W4200047841 hasAuthorship W4200047841A5047931301 @default.
• W4200047841 hasAuthorship W4200047841A5059959150 @default.
• W4200047841 hasAuthorship W4200047841A5065914659 @default.
• W4200047841 hasAuthorship W4200047841A5067708123 @default.
• W4200047841 hasAuthorship W4200047841A5067773219 @default.
• W4200047841 hasAuthorship W4200047841A5069883240 @default.
• W4200047841 hasAuthorship W4200047841A5072476030 @default.
• W4200047841 hasAuthorship W4200047841A5088147193 @default.
• W4200047841 hasAuthorship W4200047841A5089282433 @default.
• W4200047841 hasBestOaLocation W42000478411 @default.
• W4200047841 hasConcept C116675565 @default.
• W4200047841 hasConcept C126322002 @default.
• W4200047841 hasConcept C14086860 @default.
• W4200047841 hasConcept C159047783 @default.
• W4200047841 hasConcept C2522874641 @default.
• W4200047841 hasConcept C2779134260 @default.
• W4200047841 hasConcept C3006700255 @default.
• W4200047841 hasConcept C3007834351 @default.
• W4200047841 hasConcept C3008058167 @default.
• W4200047841 hasConcept C524204448 @default.
• W4200047841 hasConcept C71924100 @default.
• W4200047841 hasConceptScore W4200047841C116675565 @default.
• W4200047841 hasConceptScore W4200047841C126322002 @default.
• W4200047841 hasConceptScore W4200047841C14086860 @default.
• W4200047841 hasConceptScore W4200047841C159047783 @default.
• W4200047841 hasConceptScore W4200047841C2522874641 @default.
• W4200047841 hasConceptScore W4200047841C2779134260 @default.
• W4200047841 hasConceptScore W4200047841C3006700255 @default.
• W4200047841 hasConceptScore W4200047841C3007834351 @default.
• W4200047841 hasConceptScore W4200047841C3008058167 @default.
• W4200047841 hasConceptScore W4200047841C524204448 @default.
• W4200047841 hasConceptScore W4200047841C71924100 @default.
• W4200047841 hasIssue "10321" @default.
• W4200047841 hasLocation W42000478411 @default.
• W4200047841 hasLocation W42000478412 @default.
• W4200047841 hasLocation W42000478413 @default.
• W4200047841 hasLocation W42000478414 @default.
• W4200047841 hasLocation W42000478415 @default.
• W4200047841 hasLocation W42000478416 @default.
• W4200047841 hasOpenAccess W4200047841 @default.
• W4200047841 hasPrimaryLocation W42000478411 @default.
• W4200047841 hasRelatedWork W3009669391 @default.
• W4200047841 hasRelatedWork W3020699490 @default.
• W4200047841 hasRelatedWork W3036314732 @default.
• W4200047841 hasRelatedWork W3084498529 @default.
• W4200047841 hasRelatedWork W3176864053 @default.
• W4200047841 hasRelatedWork W3198183218 @default.
• W4200047841 hasRelatedWork W4205317059 @default.
• W4200047841 hasRelatedWork W4206669628 @default.
• W4200047841 hasRelatedWork W4292098121 @default.
• W4200047841 hasRelatedWork W4382894326 @default.
• W4200047841 hasVolume "399" @default.
• W4200047841 isParatext "false" @default.
• W4200047841 isRetracted "false" @default.
• W4200047841 workType "article" @default.